PALI
HealthcarePalisade Bio, Inc.
$2.10
$-0.40 (-16.00%)
Jan 5, 2026
Price History (1Y)
Analysis
Palisade Bio, Inc. is a biotechnology company in the healthcare sector with a relatively small scale, employing 8 individuals. The company's financial health reveals significant losses, as evident from its net income of -$11,226,000 and EBITDA of -$11,454,000 over the trailing twelve months. This has led to zero profitability margins across various measures: gross margin, operating margin, and profit margin are all 0.0%. Additionally, Palisade Bio's returns on equity and assets are substantial losses of -228.6% and -87.8%, respectively. Its balance sheet shows moderate debt levels relative to equity, with a debt-to-equity ratio of 6.57. The company has cash reserves of $5.23 million but is carrying significant debt. In terms of valuation context, Palisade Bio's market capitalization is substantial at $313.33 million, although its forward P/E and EV/EBITDA ratios are notably negative at -9.55 and -32.08, respectively. The company's price-to-book ratio stands at 5.97, indicating a premium valuation.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Palisade Bio, Inc.
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor that is in phase 1a/b clinical trial for the treatment of ulcerative colitis, as well as under phase 1a clinical trial for the treatment of fibrostenotic crohn's disease. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company is headquartered in Carlsbad, California.
Visit website →Key Statistics
- Market Cap
- $313.33M
- P/E Ratio
- N/A
- 52-Week High
- $2.64
- 52-Week Low
- $0.53
- Avg Volume
- 5.56M
- Beta
- 1.62
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 8